Ovarian Suppression Combined with Tamoxifen May Help Premenopausal Patients
A phase III study found that adding 2 years of ovarian function suppression to tamoxifen extended disease-free survival in certain patients with hormone receptor-positive breast cancer.
Study Shows Niraparib Extends Time Without Symptoms, Toxicity in Ovarian Cancer
A new study shows promising results for niraparib in the treatment of patients with ovarian cancer.
Ridad and McKaig Discuss Oncology Nurse Perceptions on Medical Cannabis
Improvements in Health Systems Model Reduces Disparities in Leukemia Survival in Low-Income Countries
Telephone and Web-Based Program Elicits Clinically Meaningful Results in Breast Cancer Survivors
Luspatercept Elicits High Transfusion Independence Rates in Lower-Risk MDS
